StreetAlpha
13F holdings · Q3 2026

Mpm Bioimpact

Boston, MA · files as Mpm Bioimpact LLC
Know the moment Mpm Bioimpact filesYou follow Mpm Bioimpact An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1687078

Mpm Bioimpact reported 36 stocks worth $1.3B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are CGEM (11.5%), AKTS (7.3%) and TVTX (4.9%). Compared with Q2 2026, the fund opened new positions in IOVA, IMCR and VIR, added to DYN, TSHA and ANL, trimmed CGEM, TVTX and EWTX and sold out of RVMD, ALMS and RARE.

Latest filing: what Mpm Bioimpact did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
9 new8 added18 trimmed10 sold outBought about $305M · sold about $390M
New 9
See all 9 →
Added 8
See all 8 →
Trimmed 18
See all 18 →
Sold out 10
See all 10 →

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$1.3B−20.8% vs last quarter · $1.3B including options
Stocks held369 new · 10 sold out
Top 5 weight32.6%spread out
Turnover53%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
CGEM
Cullinan Therapeutics Inc
$149M11.5%9.7M−10K (−0%)8 of 8
2
AKTS
Aktis Oncology Inc
$94.2M7.3%4.8MNo change3 of 8
3
TVTX
Travere Therapeutics Inc
$64.1M4.9%1.1M−34K (−3%)3 of 8
4
EWTX
Edgewise Therapeutics Inc
$64M4.9%1.6M−45K (−3%)8 of 8
5
DYN
Dyne Therapeutics Inc
$51.7M4.0%3.2M+1.3M (+67%)6 of 8
6
CORT
Corcept Therapeutics Inc
$48.6M3.7%422K−349K (−45%)3 of 8
7
RLAY
Relay Therapeutics Inc
$42.8M3.3%2.4M−46K (−2%)8 of 8
8
TRVI
Trevi Therapeutics Inc
$42.7M3.3%3M−95K (−3%)8 of 8
9
IOVA
Iovance Biotherapeutics Inc
$42M3.2%2.8MNew position3 of 8
10
LQDA
Liquidia Corporation
$40.6M3.1%1.3M−43K (−3%)5 of 8
🔒 26 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
RVMD
Revolution Medicines Inc
$92.2M492K
ALMS
Alumis Inc
$56.8M2M
RARE
Ultragenyx Pharmaceutical in
$47.4M1.4M
DNTH
Dianthus Therapeutics Inc
$40.9M420K
MLTX
Moonlake Immunotherapeutics
$31.3M1.6M

🔒 Free account: see all 10.

Options

valued at the underlying shares
StockTypeValueSharesChange
CORT
Corcept Therapeutics Inc
Put$48.6M422K+422,000

Reported value

last 8 quarters
$704MQ4 '24
$582MQ1 '25
$577MQ2 '25
$611MQ3 '25
$874MQ4 '25
$1.3BQ1 '26
$1.6BQ2 '26
$1.3BQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Mpm Bioimpact 13F FAQ

What does Mpm Bioimpact own?

Mpm Bioimpact reported 36 stocks worth $1.3B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are CGEM (11.5%), AKTS (7.3%) and TVTX (4.9%). The table above lists every position in the filing (the top 10 without an account).

What did Mpm Bioimpact buy and sell in Q3 2026?

Compared with Q2 2026: 9 new positions, 8 added to, 18 trimmed and 10 sold out. New positions include IOVA, IMCR and VIR. It sold all of RVMD, ALMS and RARE.

When will Mpm Bioimpact file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Mpm Bioimpact's portfolio worth?

The Q3 2026 filing reports $1.3B in US stocks ($1.3B including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.